{
    "SPADE_UN_11699": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_11699",
            "Peptide Name": "IN3(designed based on indolicidin and ranalexin)",
            "Source": "Synthetic construct",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "RRPWRWPRWPWRR",
            "Sequence Length": 13,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Synthetic",
            "Biological Activity": [
                "Antimicrobial",
                "Antibacterial",
                "Anti-Gram+",
                "Anti-Gram-"
            ],
            "Target Organism": "[Ref.26046345] Gram-negative bacteria:Escherichia coli ATCC 25922(MIC=31.25μg/ml), Pseudomonas aeruginosa ATCC 15442(MIC=31.25μg/ml), Acinetobacter baumanii ATCC 15308(MIC>250μg/ml), citrobacter spp(MIC>250μg/ml), Klebsiella pneumoniae(MIC>250μg/ml) ;Gram-positive bacteria:Streptococcus pneumoniae(30 clinical isolates)(MIC=62.5μg/ml), Staphylococcus aureus ATCC 25923(MIC=31.25μg/ml), Methicillin resistant Staphylococcus aureus (MRSA)(MIC=62.5μg/ml), Enterococcus cloacae(MIC>250μg/ml),",
            "Hemolytic Activity": "[Ref.26046345] The hemolytic activities of IN3 is 2.39% at 250μg/ml against human RBCs.",
            "Cytotoxicity": "[Ref.26046345] The cell viability of NL-20 cell line is not affected (<10%) below 62.5 μg/ml. The cell viability of NL-20 is 93% and 26% at peptide concentrations of 125 and 250 μg/ml.The cell viability of WRL-68 cell line is not affected (<10%) bel",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C95H135N35O14",
            "Mass": 1991.31,
            "PI": 12.0,
            "Net Charge": 6,
            "Hydrophobicity": -2.72,
            "Half Life": "Mammalian:1 hourYeast:2 minE.coli:2 min",
            "Function": "Exhibits antimicrobial activity against the Gram-positive and Gram-negative bacteria.",
            "Literature": [
                {
                    "Title": "Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae.",
                    "Pubmed ID": "26046345",
                    "Reference": "PLoS One. 2015 Jun 5;10(6)e0128532.",
                    "Author": "Jindal HM, Le CF, Mohd Yusof MY, Velayuthan RD, Lee VS, Zain SM, Isa DM, Sekaran SD.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=26046345"
                }
            ],
            "Frequent Amino Acids": "RWP",
            "Absent Amino Acids": "ACDEFGHIKLMNOQSTUVY",
            "Basic Residues": 6,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 7,
            "Polar Residues": 6,
            "Positive Residues": 6,
            "Negative Residues": 0,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_10809",
                    "Similarity": 1.0,
                    "Sequence": "YPYYGTNLYQRRPAIAINNPYVPRTYYANPAVVRPHAQIPQRQYLPNSHPPTVVRRP"
                },
                {
                    "SPADE_ID": "SPADE_N_13258",
                    "Similarity": 1.0,
                    "Sequence": "KWLRRPWRWWR"
                },
                {
                    "SPADE_ID": "SPADE_UN_02979",
                    "Similarity": 1.0,
                    "Sequence": "PRISRRRPW"
                }
            ]
        }
    }
}